KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Incyte (INCY) Research & Development (2016 - 2026)

Incyte filings provide 17 years of Research & Development readings, the most recent being $515.9 million for Q1 2026.

  • For the quarter ending Q1 2026, Research & Development rose 17.98% year-over-year to $515.9 million, compared with a TTM value of $1.5 billion through Mar 2026, down 41.32%, and an annual FY2025 reading of $2.1 billion, down 21.36% over the prior year.
  • Research & Development hit $515.9 million in Q1 2026 for Incyte, up from $17.1 million in the prior quarter.
  • The five-year high for Research & Development was $1.1 billion in Q2 2024, with the low at $17.1 million in Q4 2025.
  • Median Research & Development over the past 5 years was $437.3 million (2025), compared with a mean of $458.4 million.
  • The sharpest move saw Research & Development surged 184.06% in 2024, then tumbled 96.33% in 2025.
  • Year by year, Research & Development stood at $501.4 million in 2022, then dropped by 11.34% to $444.5 million in 2023, then grew by 4.85% to $466.0 million in 2024, then plummeted by 96.33% to $17.1 million in 2025, then skyrocketed by 2916.98% to $515.9 million in 2026.
  • According to Business Quant data, Research & Development over the past three periods came in at $515.9 million, $17.1 million, and $506.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.